Open access
1,501
Views
0
CrossRef citations to date
0
Altmetric
Hematology
Real-world time to discontinuation of first-line venetoclax + obinutuzumab in chronic lymphocytic leukemia/small lymphocytic lymphoma
Xiaoxiao Lua Janssen Scientific Affairs, LLC, Horsham, PA, USA
, Bruno Emondb Analysis Group, Inc, Montréal, CanadaCorrespondence[email protected]
https://orcid.org/0000-0002-0060-765X
Zaina P. Qureshia Janssen Scientific Affairs, LLC, Horsham, PA, USA
, Linda H. Wua Janssen Scientific Affairs, LLC, Horsham, PA, USA
, Shaun P. Forbesc Analysis Group, Inc, Menlo Park, CA, USA
, Annalise Hiltsb Analysis Group, Inc, Montréal, Canada
, Stephanie Liuc Analysis Group, Inc, Menlo Park, CA, USA
, Marie-Hélène Lafeuilleb Analysis Group, Inc, Montréal, Canada
, Patrick Lefebvreb Analysis Group, Inc, Montréal, Canada
, Qing Huanga Janssen Scientific Affairs, LLC, Horsham, PA, USA
& Kerry A. Rogersd Division of Hematology, The Ohio State University, Columbus, OH, USA
show all
Pages 1227-1235
|
Received 14 Jun 2023, Accepted 31 Jul 2023, Published online: 21 Aug 2023
Reprints and Permissions
Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.
To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.
For more information please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.